LA-EP2006: A Pegfilgrastim Biosimilar.
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 229, doi. 10.1007/s40259-019-00348-3
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2019 AND VI 33 AND IP 2
Results: 10
1
2
Vestronidase Alfa: A Review in Mucopolysaccharidosis VII.
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 233, doi. 10.1007/s40259-019-00344-7
- By:
- Publication type:
- Article
3
PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen<sup>®</sup>): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 207, doi. 10.1007/s40259-019-00343-8
- By:
- Publication type:
- Article
4
Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 193, doi. 10.1007/s40259-019-00342-9
- By:
- Publication type:
- Article
5
Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals.
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 183, doi. 10.1007/s40259-019-00341-w
- By:
- Publication type:
- Article
6
A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 173, doi. 10.1007/s40259-019-00340-x
- By:
- Publication type:
- Article
7
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 159, doi. 10.1007/s40259-019-00339-4
- By:
- Publication type:
- Article
8
The Relationship between Exosomes and Cancer: Implications for Diagnostics and Therapeutics.
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 137, doi. 10.1007/s40259-019-00338-5
- By:
- Publication type:
- Article
9
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 125, doi. 10.1007/s40259-019-00337-6
- By:
- Publication type:
- Article
10
In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima<sup>®</sup>) Following Preparation for Intravenous Infusion and Storage.
- Published in:
- BioDrugs, 2019, v. 33, n. 2, p. 221, doi. 10.1007/s40259-019-00336-7
- By:
- Publication type:
- Article